CovarsaDx, a leading contract research organization (CRO) specializing in the areas of in vitro diagnostics (IVD) and medical device clinical […]
As respiratory illness season looms, bringing with it the usual suspects – COVID-19, influenza, and RSV – the demand for accurate and timely diagnostics has never been higher. With symptoms that blur the lines between these viruses, especially during peak seasons, healthcare providers are under pressure to deliver swift, precise diagnoses.
CovarsaDx to Highlight Integrated Clinical Trial Expertise at ADLM 2025 CovarsaDx, a leading medical device and diagnostics clinical research organization
At CovarsaDx, we’ve earned a solid reputation in respiratory diagnostics, helping companies like OSANG Healthcare, Nuclein, and Healgen bring their
What Every Sponsor Should Know About IVD and Medical Device Clinical Research Right Now By Clara Feider, PhD, CCRASr. Clinical
Los Angeles, Calif., February 10, 2025 – CovarsaDx, a prominent Clinical Research Organization (CRO) well-known for its expertise in the areas
CovarsaDx, a leader in IVD and medical device clinical trials, faced a common challenge: efficiently managing vast amounts of complex
CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its expertise in the areas of in-vitro diagnostics (IVDs) and medical
CovarsaDx®, a prominent Clinical Research Organization (CRO) renowned for its in vitro diagnostics (IVDs) and medical device expertise, announced today that one of its clinical research study clients, Nuclein, LLC, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver for the DASH® SARS-CoV-2 & Flu A/B Test for use on the DASH® Rapid PCR System.
As we reflect on 2024, CovarsaDx has much to celebrate. This year was marked by milestones that showcased our commitment to advancing diagnostic innovation